Biosimilars Connect
  • Saved

1mo
Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations. - PubMed

Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41999443

Discover ustekinumab biosimilars in IBD care, highlighting FDA approval context and patient-centered strategies.


Ustekinumab biosimilars, FDA-approved via psoriasis studies, show efficacy and safety in IBD care.

  • Saved

1mo

When transitioning a stable patient to a biosimilar, which factor most influences your approach?

  • Saved

2mo
Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization: A Scoping Review. - PubMed

Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization: A Scoping Review. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42218738

Explore global biosimilar regulation challenges, including comparability exercises and clinical study waivers, impacting medication access and pricing in this comprehensive review.


This review highlights global inconsistencies in biosimilar regulations, including differences in comparability exercises, nonlocal comparators, and clinical study waivers, affecting access and pricing.

  • Saved

2mo
First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety. - PubMed

First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42220514

Explore potential survival benefits of first-line immunotherapy in advanced hepatocellular carcinoma, particularly in HBV cases, without increased severe toxicity.


First-line immunotherapy may offer survival benefits over TKI monotherapy in advanced hepatocellular carcinoma, especially in HBV-positive cases, without increased severe toxicity.

  • Saved

1yr
Emerging Myositis Treatments and Targeted Therapies – Insights from IgNS 2024

In this IgNS 2024 conference video, Dr. Eleni Tiniakou, a rheumatologist and assistant professor at Johns Hopkins, shares advancements in myositis treatment approaches. She highlights evidence-based therapies, including interferon pathway inhibitors, B-cell targeting, and early research on CAR T-cell applications. Dr. Tiniakou emphasizes the importance of personalized approaches to address the diverse pathogenic factors in myositis treatment. These insights provide physicians tools to better tailor treatments across myositis subtypes and improve patient outcomes.